ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 58 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 2.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,600,718 | -12.2% | 333,483 | +37.3% | 0.00% | – |
Q2 2023 | $1,823,774 | +28.4% | 242,846 | -22.7% | 0.00% | – |
Q1 2023 | $1,420,123 | -74.1% | 314,186 | -35.4% | 0.00% | -100.0% |
Q4 2022 | $5,480,803 | +44.4% | 486,318 | +22.6% | 0.00% | 0.0% |
Q3 2022 | $3,796,000 | +5.7% | 396,637 | -10.7% | 0.00% | – |
Q2 2022 | $3,592,000 | -44.7% | 443,935 | +15.5% | 0.00% | -100.0% |
Q1 2022 | $6,497,000 | +18.7% | 384,518 | +51.0% | 0.00% | 0.0% |
Q4 2021 | $5,473,000 | -9.0% | 254,700 | +212.8% | 0.00% | 0.0% |
Q3 2021 | $6,014,000 | +8.9% | 81,420 | -19.4% | 0.00% | 0.0% |
Q2 2021 | $5,523,000 | +1543.8% | 101,009 | +2116.6% | 0.00% | – |
Q1 2021 | $336,000 | -69.0% | 4,557 | -63.7% | 0.00% | – |
Q4 2020 | $1,083,000 | +1404.2% | 12,564 | +561.6% | 0.00% | – |
Q3 2020 | $72,000 | – | 1,899 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |